This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Esper, D. H. Articles by Harb, W. A. Search for Related Content PubMed PubMed Citation Articles by Esper, D. H. Articles by Harb, W. A. Social Bookmarking                         What's this?

The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations

Dema Halasa Esper, MS, RD, CNSD^*
Wael A. Harb, MD^*,,

^* Horizon Oncology, Lafayette, Indiana; The Care Group LLC, Indianapolis, IN; and Indiana University, Indianapolis, Indiana

Correspondence: Correspondence: Dema Halasa Esper, MS, RD, CNSD, 1345 Unity Place, Suite 345, Lafayette, IN 47905. Electronic mail may be sent to dhalasa_esper{at}yahoo.com.

The progressive deterioration in nutrition status frequently seen in cancer patients is often referred to as cancer cachexia. Unlike starvation, in which fat stores from adipose are depleted and protein is spared from skeletal muscle, neither fat nor protein is spared in cachexia. Cachexia affects nearly half of cancer patients, causing the clinical manifestations of anorexia, muscle wasting, weight loss, early satiety, fatigue, and impaired immune response. Cachexia does not only impede the response to chemotherapy but also is a major cause of morbidity and mortality. According to clinical studies, increasing caloric intake does not necessarily reverse cachexia. The pathophysiology of cachexia involves more complex mechanisms than simply caloric deficiency. The process appears to be mediated by circulating catabolic factors, either secreted by the tumor alone or in concert with host-derived factors, such as tumor necrosis factor- (TNF-), interleukins (IL-1 and IL-6), interferon (IFN-y), and leukemia inhibitory factor (LIF). The successful reversal of this process will require in-depth knowledge of the mechanisms involved, which will then enable the development of effective pharmacologic interventions that may not only improve quality of life, but more importantly, improve survival among cancer patients.

Nutrition in Clinical Practice, Vol. 20, No. 4, 369-376 (2005)
DOI: 10.1177/0115426505020004369


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Vujovic, K. Nordstrom, K. Gauthier, F. Flamant, T. J. Visser, B. Vennstrom, and J. Mittag Interference of a Mutant Thyroid Hormone Receptor {alpha}1 with Hepatic Glucose Metabolism Endocrinology, June 1, 2009; 150(6): 2940 - 2947. [Abstract] [Full Text] [PDF]

				J. Laurencikiene, B. M. Stenson, E. Arvidsson Nordstrom, T. Agustsson, D. Langin, B. Isaksson, J. Permert, M. Ryden, and P. Arner Evidence for an Important Role of CIDEA in Human Cancer Cachexia Cancer Res., November 15, 2008; 68(22): 9247 - 9254. [Abstract] [Full Text] [PDF]

				J. M. Mercader, J. J. Lozano, L. Sumoy, M. Dierssen, J. Visa, M. Gratacos, and X. Estivill Hypothalamus transcriptome profile suggests an anorexia-cachexia syndrome in the anx/anx mouse model Physiol Genomics, November 12, 2008; 35(3): 341 - 350. [Abstract] [Full Text] [PDF]

				R. D. Winfield, M. J. Delano, K. Pande, P. O. Scumpia, D. LaFace, and L. L. Moldawer Myeloid-Derived Suppressor Cells in Cancer Cachexia Syndrome: A New Explanation for an Old Problem JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 651 - 655. [Abstract] [Full Text] [PDF]

				G. E. Hermann and R. C. Rogers TNF {alpha}: A Trigger of Autonomic Dysfunction Neuroscientist, February 1, 2008; 14(1): 53 - 67. [Abstract] [PDF]

				K. F. Tacer, D. Kuzman, M. Seliskar, D. Pompon, and D. Rozman TNF-{alpha} interferes with lipid homeostasis and activates acute and proatherogenic processes Physiol Genomics, October 19, 2007; 31(2): 216 - 227. [Abstract] [Full Text] [PDF]

				T. Agustsson, M. Ryden, J. Hoffstedt, V. van Harmelen, A. Dicker, J. Laurencikiene, B. Isaksson, J. Permert, and P. Arner Mechanism of Increased Lipolysis in Cancer Cachexia Cancer Res., June 1, 2007; 67(11): 5531 - 5537. [Abstract] [Full Text] [PDF]

				M. Dehoux, C. Gobier, P. Lause, L. Bertrand, J.-M. Ketelslegers, and J.-P. Thissen IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E145 - E150. [Abstract] [Full Text] [PDF]

				M. D. Carmichael, J. M. Davis, E. A. Murphy, A. S. Brown, J. A. Carson, E. P. Mayer, and A. Ghaffar Role of brain IL-1beta on fatigue after exercise-induced muscle damage Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1344 - R1348. [Abstract] [Full Text] [PDF]